1. Endolymphatic Sac Tumors Associated With von Hippel-Lindau: A Case Report Highlighting Opportunity for Novel Orphan Drug Therapy.
- Author
-
Tan D, Fujiwara RJT, Tan C, Isaacson B, and Hunter JB
- Subjects
- Humans, Female, Treatment Outcome, Kidney Neoplasms drug therapy, Carcinoma, Renal Cell drug therapy, Adult, Middle Aged, Endolymphatic Sac surgery, Endolymphatic Sac pathology, von Hippel-Lindau Disease complications, Ear Neoplasms diagnostic imaging, Ear Neoplasms complications, Ear Neoplasms pathology
- Abstract
Objective: To discuss the potential benefit of belzutifan therapy in a patient with von Hippel-Lindau (VHL) disease-associated endolymphatic sac tumor (ELST)., Patients: Case report., Interventions: Clinical details of a patient with residual ELST after hearing preservation surgery who initiated belzutifan therapy postoperatively for concurrent renal cell carcinoma, as well as literature review of belzutifan and ELST., Main Outcome Measures: The patient remained without radiologic evidence of growth of her residual tumor at 17 months post-initiation of belzutifan. It is unknown whether this represents therapeutic drug effect, nonviability of residual tumor, or slow tumor growth not captured radiographically within the duration of follow-up., Conclusions: Belzutifan could have direct therapeutic benefit in patients with VHL-associated ELST., Competing Interests: The authors otherwise have no relevant disclosures with regard to financial support, acknowledgement, or conflicts of interest., (Copyright © 2024, Otology & Neurotology, Inc.)
- Published
- 2024
- Full Text
- View/download PDF